CRVS — Corvus Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $247.33m
- $195.37m
Annual cashflow statement for Corvus Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -6 | -43.2 | -41.3 | -27 | -62.3 |
| Depreciation | |||||
| Non-Cash Items | -31.3 | 9.3 | 12.5 | 6.54 | 38.4 |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 1.91 | -3.24 | 1.41 | -3.59 | -1.65 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Cash from Operating Activities | -34.8 | -36.7 | -27 | -23.9 | -25.4 |
| Capital Expenditures | -0.076 | -0.005 | -0.269 | -0.034 | — |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 44.8 | 21.6 | -23 | 15.6 | -27.5 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Change in Net Investments | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 44.8 | 21.6 | -23.3 | 15.5 | -27.5 |
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 1.31 | 62.2 | 0 | 7.86 | 49 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 11.3 | 47 | -50.3 | -0.539 | -3.88 |